102 related articles for article (PubMed ID: 17227493)
1. Early effects of pharmacological androgen deprivation in human prostate cancer.
Mercader M; Sengupta S; Bodner BK; Manecke RG; Cosar EF; Moser MT; Ballman KV; Wojcik EM; Kwon ED
BJU Int; 2007 Jan; 99(1):60-7. PubMed ID: 17227493
[TBL] [Abstract][Full Text] [Related]
2. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
3. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
Ohlson N; Bergh A; Nygren K; Stattin P; Wikström P
Eur Urol; 2006 Apr; 49(4):675-83. PubMed ID: 16387414
[TBL] [Abstract][Full Text] [Related]
4. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
5. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
7. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
8. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment.
Ohlson N; Wikström P; Stattin P; Bergh A
Prostate; 2005 Mar; 62(4):307-15. PubMed ID: 15389788
[TBL] [Abstract][Full Text] [Related]
9. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
10. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
11. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.
Benaim EA; Karam JA; Soboorian MH; Roehrborn CG; McConnell JD; Lin V
Prostate; 2004 Sep; 60(4):310-6. PubMed ID: 15264242
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
13. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
14. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
15. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
16. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
[TBL] [Abstract][Full Text] [Related]
17. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma.
Têtu B
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):271-83. PubMed ID: 18471785
[TBL] [Abstract][Full Text] [Related]
18. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
He D; Falany CN
Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
[TBL] [Abstract][Full Text] [Related]
20. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
